



Universiteit  
Leiden  
The Netherlands

## **Integrating clinicopathological and molecular data in the breast cancer patient : towards precision medicine**

Engels, C.C.

### **Citation**

Engels, C. C. (2016, May 19). *Integrating clinicopathological and molecular data in the breast cancer patient : towards precision medicine*. Retrieved from <https://hdl.handle.net/1887/39789>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/39789>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/39789> holds various files of this Leiden University dissertation

**Author:** Engels, Charla Chábeli

**Title:** Integrating clinicopathological and molecular data in the breast cancer patient :  
towards precision medicine

**Issue Date:** 2016-05-19

**INTEGRATING CLINICOPATHOLOGICAL AND MOLECULAR DATA IN THE  
BREAST CANCER PATIENT**

*Towards precision medicine*

Charla Chábeli Engels



**INTEGRATING CLINICOPATHOLOGICAL AND MOLECULAR DATA IN THE  
BREAST CANCER PATIENT**

*Towards precision medicine*

Proefschrift

Ter verkrijging van  
de graad van Doctor aan de Universiteit Leiden,  
op gezag van de Rector Magnificus prof. mr. C.J.J.M. Stolker,  
volgens besluit van het College voor Promoties  
te verdedigen op donderdag 19 mei 2016  
klokke 13.45 uur

door

**Charla Chábeli Engels**

geboren te Curaçao

in 1986

<b>Promotor</b>	Prof. dr. C.J.H. van de Velde
<b>Co-promotor(en)</b>	Dr. G.J. Liefers Dr. P.J.K. Kuppen
<b>Leden promotiecommissie</b>	Prof. dr. V.T.H.B.M. Smit Prof. dr. ir. J. J. M. van der Hoeven, Radboudumc/LUMC Prof. dr. S.C. Linn, AvL Dr. C. M. Seynaeve, Erasmus MC

Printing of this thesis was financially supported by:  
ChipSoft B.V., Boehringer-Ingelheim B.V., and Greiner Bio-One B.V.

## CONTENTS

<b>Chapter 1.</b>	General introduction	7
-------------------	----------------------	---

### ***Part I. Prognostic biomarkers in breast cancer***

<b>Chapter 2.</b>	The prognostic value of apoptotic and proliferative biomarkers in breast cancer	25
-------------------	---	----

<b>Chapter 3.</b>	Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients	49
-------------------	---	----

<b>Chapter 4.</b>	Immunological subtypes in breast cancer are prognostic for invasive ductal but not for invasive lobular breast carcinoma	79
-------------------	--	----

<b>Chapter 5.</b>	The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor positive breast cancer patients treated with adjuvant endocrine therapy: A Dutch TEAM Study Analysis	95
-------------------	---	----

<b>Chapter 6.</b>	The clinical prognostic value of molecular intrinsic tumor subtypes in older breast cancer patients: a FOCUS study analysis	121
-------------------	---	-----

### ***Part II. Predictive biomarkers in breast cancer and targeted treatment***

<b>Chapter 7.</b>	The influence of Insulin-like Growth Factor-1-Receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer patients: A Dutch TEAM substudy analysis	139
-------------------	--	-----

<b>Chapter 8.</b>	The clinical value of HER-2 ( <i>ERBB2</i> ) overexpression and PIK3CA mutations in the older breast cancer population: A FOCUS Study analysis	157
-------------------	--	-----

### ***Part III. Aging in the breast cancer patient***

<b>Chapter 9.</b>	HIF1 $\alpha$ and its metabolic targets are highly expressed in breast tumors of patients of 65 years or older but not in patients younger than 65 years of age	179
-------------------	---	-----

<b>Chapter 10.</b>	HIF1 $\alpha$ and PKM2 are important drivers of age associated clinical functional decline and disease in the elderly breast cancer population: A FOCUS study analysis	199
--------------------	--	-----

### ***Part IV. Precision medicine in the (older) breast cancer patient***

<b>Chapter 11.</b>	How does genome sequencing impact surgery?	235
--------------------	--	-----

<b>Chapter 12.</b>	General discussion	261
--------------------	--------------------	-----

### ***Appendices.***

Nederlandse samenvatting	287
List of publications	305
List of co-authors	309
Curriculum vitae	313
Dankwoord/Acknowledgements	315

